ART6043 / Artios Pharma - LARVOL DELTA

DNA polymerase theta inhibitor, ART6043, potentiates the efficacy of 177Lu- and 225Ac-based radioligand therapies in vitro and in vivo (AACR 2025) - "This potential is pertinent to cancer therapy, as radioligand therapy (RLT), where a radionuclide is targeted to tumour cells by linking to peptides binding tumour-specific receptors, has had recent clinical success, in particular with 177Lu-PSMA-617 for prostate cancer. Key findings were confirmed for the combination of ART6043 with 225Ac-RLT.Furthermore, in vivo studies in mouse prostate cancer xenografts showed that the combination of ART6043 with 177Lu-RLT induced significant tumour growth inhibition and a significant improvement in median survival with regimens that were well tolerated. This work supports the clinical development of the combination of ART6043 with RLT to improve the clinical efficacy of RLT."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • POLQ

Artios Pharma Announces Details of Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) - "Artios Pharma Limited...today announced that the company’s abstract featuring clinical trial results from its ongoing Phase 1/2a study of ART0380 in combination with low dose irinotecan has been selected for an oral presentation at the American Association for Cancer Research ('AACR') Annual Meeting 2025, taking place in Chicago from April 25 to 30, 2025."

P1/2 data • Preclinical • Solid Tumor

ART6043: a first-in-class clinical DNA Polymerase Theta polymerase domain inhibitor for potentiating PARP inhibitor efficacy (EORTC-NCI-AACR 2024) - P1/2 | "The data presented demonstrate strong potential for ART6043 as an anti-cancer therapeutic for HRD tumours in combination with PARP inhibitors."

Clinical • Oncology • POLQ

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov) - P1/2 | N=250 | Recruiting | Sponsor: Artios Pharma Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Monotherapy • Breast Cancer • HER2 Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • HER-2

Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (clinicaltrials.gov) - P1/2 | N=250 | Not yet recruiting | Sponsor: Artios Pharma Ltd

Metastases • Monotherapy • New P1/2 trial • Breast Cancer • HER2 Breast Cancer • Oncology • Prostate Cancer • Solid Tumor • HER-2